首页> 外文期刊>Cancer Cell International >Sporadic PCDH18 somatic mutations in EpCAM-positive hepatocellular carcinoma
【24h】

Sporadic PCDH18 somatic mutations in EpCAM-positive hepatocellular carcinoma

机译:EpCAM阳性肝细胞癌中偶发的PCDH18体细胞突变

获取原文
           

摘要

The relationship between specific genome alterations and hepatocellular carcinoma (HCC) cancer stem cells (CSCs) remains unclear. In this study, we evaluated the relationship between somatic mutations and epithelial cell adhesion molecule positive (EpCAM+) CSCs. Two patient-derived HCC samples (HCC1 and HCC2) were sorted by EpCAM expression and analyzed by whole exome sequence. We measured PCDH18 expression level in eight HCC cell lines as well as HCC1 and HCC2 by real-time quantitative RT-PCR. We validated the identified gene mutations in 57 paired of HCC and matched non-cancerous liver tissues by Sanger sequence. Whole exome sequencing on the sorted EpCAM+ and EpCAM− HCC1 and HCC2 cells revealed 19,263 nonsynonymous mutations in the cording region. We selected mutations that potentially impair the function of the encoded protein. Ultimately, 60 mutations including 13 novel nonsense and frameshift mutations were identified. Among them, PCDH18 mutation was more frequently detected in sorted EpCAM+ cells than in EpCAM− cells in HCC1 by whole exome sequences. However, we could not confirm the difference of PCDH18 mutation frequency between sorted EpCAM+ and EpCAM− cells by Sanger sequencing, indicating that PCDH18 mutation could not explain intracellular heterogeneity. In contrast, we found novel PCDH18 mutations, including c.2556_2557delTG, c.1474CG, c.2337AG, and c.2976GT, were detected in HCC1 and 3/57 (5.3%) additional HCC surgical specimens. All four HCCs with PCDH18 mutations were EpCAM-positive, suggesting that PCDH18 somatic mutations might explain the intertumor heterogeneity of HCCs in terms of the expression status of EpCAM. Furthermore, EpCAM-positive cell lines (Huh1, Huh7, HepG2, and Hep3B) had lower PCDH18 expression than EpCAM-negative cell lines (PLC/PRL/5, HLE, HLF, and SK-Hep-1), and PCDH18 knockdown in HCC2 cells slightly enhanced cell proliferation. Our data suggest that PCDH18 is functionally suppressed in a subset of EpCAM-positive HCCs through somatic mutations, and may play a role in the development of EpCAM-positive HCCs.
机译:特定基因组改变与肝细胞癌(HCC)癌症干细胞(CSC)之间的关系仍不清楚。在这项研究中,我们评估了体细胞突变与上皮细胞粘附分子阳性(EpCAM +)CSC之间的关系。通过EpCAM表达对两个患者来源的HCC样本(HCC1和HCC2)进行分类,并通过整个外显子组序列进行分析。我们通过实时定量RT-PCR测量了8种HCC细胞系以及HCC1和HCC2中PCDH18的表达水平。我们通过Sanger序列验证了57对HCC和匹配的非癌性肝组织中已鉴定的基因突变。对分类的EpCAM +和EpCAM- HCC1和HCC2细胞进行的整个外显子组测序显示,在连接区域存在19,263个非同义突变。我们选择了可能损害编码蛋白功能的突变。最终,鉴定出60个突变,包括13个新的无意义和移码突变。其中,通过完整的外显子组序列,在排序的EpCAM +细胞中检测到的PCDH18突变比在HCC1中的EpCAM-细胞检测到的多。但是,我们无法通过Sanger测序证实分选的EpCAM +和EpCAM-细胞之间PCDH18突变频率的差异,这表明PCDH18突变无法解释细胞内异质性。相反,我们发现在HCC1和3/57(5.3%)的其他HCC手术标本中检测到了新的PCDH18突变,包括c.2556_2557delTG,c.1474C> G,c.2337A> G和c.2976G> T。具有PCDH18突变的所有四个HCC均为EpCAM阳性,这表明PCDH18体细胞突变可能从EpCAM的表达状态解释了HCC的肿瘤间异质性。此外,EpCAM阳性细胞系(Huh1,Huh7,HepG2和Hep3B)的PCDH18表达低于EpCAM阴性细胞系(PLC / PRL / 5,HLE,HLF和SK-Hep-1),而PCDH18敲低HCC2细胞略微增强细胞增殖。我们的数据表明PCDH18在功能上通过体细胞突变在EpCAM阳性HCC的一个子集中受到抑制,并且可能在EpCAM阳性HCC的发展中发挥作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号